Literature DB >> 9659234

Activation of complement by human IgG1 and human IgG3 antibodies against the human leucocyte antigen CD52.

S Redpath1, T Michaelsen, I Sandlie, M R Clark.   

Abstract

Activation of the complement cascade by immunoglobulin G (IgG) plays a major role in the host defense against pathogens. Using recombinant human antibodies specific for the leucocyte antigen CD52, different allotypes of human IgG1 subclass were compared for their ability to activate human complement. In addition the roles of the different length hinge regions of IgG1 and IgG3 were investigated. It was found that the naturally occurring allotypes G1m(a,z) and G1m(f), and one artificially created isoallotype, G1m(null), did not significantly differ in their overall ability to cause cell lysis. However, some differences in binding of individual components of the classical activation pathway were detected. More of the complement component C1s seemed to be associated with the allotype G1m(f), although this did not result in an overall improvement in lytic potency. In this system the wild-type IgG3 was found to be less effective in complement lysis than IgG1. By shortening the hinge region of IgG3 to resemble that of an IgG1 antibody, increased complement binding was observed compared with that of wild-type IgG3 and the IgG1 allotypes. The overall lytic potency of the antibody was also improved compared with wild type IgG3 and it was also slightly more effective than the IgG1 allotypes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9659234      PMCID: PMC1364140          DOI: 10.1046/j.1365-2567.1998.00472.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  14 in total

Review 1.  Allotypes and other epitopes of immunoglobulins.

Authors:  G G de Lange
Journal:  Baillieres Clin Haematol       Date:  1991-12

2.  Flexibility of human IgG subclasses.

Authors:  K H Roux; L Strelets; T E Michaelsen
Journal:  J Immunol       Date:  1997-10-01       Impact factor: 5.422

Review 3.  C1: molecular interactions with activating systems.

Authors:  R B Sim; K B Reid
Journal:  Immunol Today       Date:  1991-09

Review 4.  Humanisation of monoclonal antibodies for therapy.

Authors:  S D Gorman; M R Clark
Journal:  Semin Immunol       Date:  1990-11       Impact factor: 11.130

5.  Rheumatoid anti Gm gactors with specificity for the pFc' subfragment of human immunoglobulin G.

Authors:  J B Natvig; M W Turner
Journal:  Nature       Date:  1970-02-28       Impact factor: 49.962

6.  The amino acid sequences of the Fd fragments of two human gamma-1 heavy chains.

Authors:  E M Press; N M Hogg
Journal:  Biochem J       Date:  1970-05       Impact factor: 3.857

7.  Localization of the binding site for the human high-affinity Fc receptor on IgG.

Authors:  A R Duncan; J M Woof; L J Partridge; D R Burton; G Winter
Journal:  Nature       Date:  1988-04-07       Impact factor: 49.962

8.  Reshaping human antibodies for therapy.

Authors:  L Riechmann; M Clark; H Waldmann; G Winter
Journal:  Nature       Date:  1988-03-24       Impact factor: 49.962

9.  Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies.

Authors:  J L Dangl; T G Wensel; S L Morrison; L Stryer; L A Herzenberg; V T Oi
Journal:  EMBO J       Date:  1988-07       Impact factor: 11.598

10.  Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies.

Authors:  M Brüggemann; G T Williams; C I Bindon; M R Clark; M R Walker; R Jefferis; H Waldmann; M S Neuberger
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

View more
  11 in total

1.  IgG1 deficiency exacerbates experimental autoimmune myasthenia gravis in BALB/c mice.

Authors:  Ruksana Huda; Richard T Strait; Erdem Tüzün; Fred D Finkelman; Premkumar Christadoss
Journal:  J Neuroimmunol       Date:  2015-03-06       Impact factor: 3.478

2.  Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions.

Authors:  Gregory L Moore; Hsing Chen; Sher Karki; Greg A Lazar
Journal:  MAbs       Date:  2010 Mar-Apr       Impact factor: 5.857

3.  Myocardial Recovery in Patients With Systolic Heart Failure and Autoantibodies Against β1-Adrenergic Receptors.

Authors:  Yuji Nagatomo; Dennis M McNamara; Jeffrey D Alexis; Leslie T Cooper; G William Dec; Daniel F Pauly; Richard Sheppard; Randall C Starling; W H Wilson Tang
Journal:  J Am Coll Cardiol       Date:  2017-02-28       Impact factor: 24.094

4.  Anti-CD20-interferon-β fusion protein therapy of murine B-cell lymphomas.

Authors:  Kham R Trinh; Alex Vasuthasawat; Kristopher K Steward; Reiko E Yamada; John M Timmerman; Sherie L Morrison
Journal:  J Immunother       Date:  2013-06       Impact factor: 4.456

5.  Investigating monoclonal antibody aggregation using a combination of H/DX-MS and other biophysical measurements.

Authors:  Roxana E Iacob; George M Bou-Assaf; Lee Makowski; John R Engen; Steven A Berkowitz; Damian Houde
Journal:  J Pharm Sci       Date:  2013-10-17       Impact factor: 3.534

6.  Hinge-Region O-Glycosylation of Human Immunoglobulin G3 (IgG3).

Authors:  Rosina Plomp; Gillian Dekkers; Yoann Rombouts; Remco Visser; Carolien A M Koeleman; Guinevere S M Kammeijer; Bas C Jansen; Theo Rispens; Paul J Hensbergen; Gestur Vidarsson; Manfred Wuhrer
Journal:  Mol Cell Proteomics       Date:  2015-03-10       Impact factor: 5.911

Review 7.  Complement in malaria immunity and vaccines.

Authors:  Liriye Kurtovic; Michelle J Boyle; D Herbert Opi; Alexander T Kennedy; Wai-Hong Tham; Linda Reiling; Jo-Anne Chan; James G Beeson
Journal:  Immunol Rev       Date:  2019-09-26       Impact factor: 12.988

Review 8.  Development of Therapeutic Antibodies and Modulating the Characteristics of Therapeutic Antibodies to Maximize the Therapeutic Efficacy.

Authors:  Seung Hyun Kang; Chang-Han Lee
Journal:  Biotechnol Bioprocess Eng       Date:  2021-06-28       Impact factor: 2.836

Review 9.  Beyond Allotypes: The Influence of Allelic Diversity in Antibody Constant Domains.

Authors:  Annmaree K Warrender; William Kelton
Journal:  Front Immunol       Date:  2020-08-18       Impact factor: 7.561

10.  Cell-free IgG-aggregates in plasma of patients with chronic lymphocytic leukemia cause chronic activation of the classical complement pathway.

Authors:  Regina Michelis; Tamar Tadmor; Ariel Aviv; Galia Stemer; Rawan Majdob; Lev Shvidel; Mona Shehadeh; Masad Barhoum; Andrei Braester
Journal:  PLoS One       Date:  2020-03-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.